Avidity Biosciences, Inc. Stock Price, News & Analysis

Avidity Biosciences (Nasdaq: RNA) has announced an upcoming investor and analyst event (Volume 11) scheduled for November 12, 2024, at 8:00 a.m. ET. The company will unveil new development candidates from its precision cardiology portfolio and showcase next-generation technology innovations.

Additionally, Avidity will present a poster on their lead precision cardiology candidate at the American Heart Association (AHA) Scientific Sessions 2024 on November 16, 2024, at 11:40 a.m. CT in Chicago. The presentation will focus on a novel precision cardiology treatment for PRKAG2 Cardiomyopathy, a subset of patients with Wolff-Parkinson-White Syndrome.

Avidity Biosciences has initiated a biomarker cohort in the Phase 1/2 FORTITUDE™ trial of delpacibart braxlosiran (del-brax) for facioscapulohumeral muscular dystrophy (FSHD). The company is pursuing an accelerated approval path, with enrollment expected to complete in 1H 2025. Initial data showed del-brax 2 mg/kg administered every six weeks achieved >50% reductions in DUX4 regulated genes, ≥25% decreases in novel circulating biomarker and creatine kinase, with trends of functional improvement. The biomarker cohort will assess del-brax's impact on patients aged 16-70, focusing on changes in DUX4 regulated gene expression and biomarkers. Del-brax is the first potential therapy targeting DUX4, the disease-causing gene in FSHD.

Cartography Biosciences has appointed Troy E. Wilson, Ph.D., J.D. as an independent director to its Board of Directors. Wilson, a 25-year biopharma industry veteran, is currently President, CEO, and co-founder of Kura Oncology (NASDAQ: KURA). He brings extensive experience in founding and leading biotech companies, including Avidity Biosciences, Araxes Pharma, and Wellspring Biosciences. Cartography, an oncology company developing antibody therapeutics, aims to leverage Wilson's expertise as it advances its pipeline of novel programs targeting tumors more precisely than existing treatments.

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company developing Antibody Oligonucleotide Conjugates (AOCs™), has granted equity awards to 34 new non-executive employees under its 2022 Employment Inducement Incentive Award Plan. The grants include:

• 421,600 non-qualified stock options to purchase common stock
• 210,800 restricted stock units (RSUs)

These awards are intended as employment inducements in compliance with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price of $50.45 per share, equal to the closing price of Avidity's common stock on October 18, 2024. The options will vest over four years, with 25% vesting after one year and the remainder vesting monthly over 36 months. RSUs will vest in four equal annual installments. All awards are subject to continued employment with Avidity.

Avidity Biosciences (Nasdaq: RNA) announced that the FDA has removed the partial clinical hold on delpacibart etedesiran (del-desiran/AOC 1001), an investigational treatment for myotonic dystrophy type 1 (DM1). Del-desiran is currently being evaluated in the Phase 3 HARBOR™ trial for DM1, a progressive and often fatal neuromuscular disease with no approved therapies.

Del-desiran is designed to address the root cause of DM1 and has received Breakthrough Therapy, Orphan Drug, and Fast Track designations from the FDA, as well as Orphan designation from the EMA. Avidity Biosciences is developing a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™).

Avidity Biosciences (Nasdaq: RNA), a biopharmaceutical company developing Antibody Oligonucleotide Conjugates (AOCs™), has announced its participation in an upcoming investor conference. The company's management will be present at the Chardan 8th Annual Genetic Medicines Conference on October 1 at 7:30 a.m. PT / 10:30 a.m. ET.

A live webcast of the event will be available, along with up-to-date details and an archived replay, on the 'Events and Presentations' page in the 'Investors' section of Avidity's website. Interested parties can access this information at https://aviditybiosciences.investorroom.com/events-and-presentations.

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company developing Antibody Oligonucleotide Conjugates (AOCs™), has granted equity awards to 21 new non-executive employees under its 2022 Employment Inducement Incentive Award Plan. The awards, approved on September 20, 2024, include:

• 212,000 non-qualified stock options with an exercise price of $44.48 per share
• 106,000 restricted stock units (RSUs)

These grants, made in accordance with Nasdaq Listing Rule 5635(c)(4), serve as employment inducements. The stock options will vest over four years, with 25% vesting after one year and the remainder monthly over 36 months. RSUs will vest in four equal annual installments. All awards are subject to continued employment and the terms of the 2022 Inducement Plan and respective agreements.

Avidity Biosciences (Nasdaq: RNA) is participating in National Muscular Dystrophy Awareness Month this September, supporting various initiatives and events. The company has reported groundbreaking data across three rare neuromuscular disease clinical programs: del-desiran™ for myotonic dystrophy type 1 (DM1), del-brax™ for facioscapulohumeral muscular dystrophy (FSHD), and del-zota™ for Duchenne muscular dystrophy amenable to exon 44 skipping (DMD44).

Avidity has initiated the global Phase 3 HARBOR™ study for DM1 and is advancing additional candidates from their DMD franchise. The company is engaging with patient communities and advocacy groups through various events, including the MDF Gala, World Duchenne Awareness Day, International Myotonic Dystrophy Awareness Day, Global Genes Week in RARE, and the FSHD Society Walk & Roll to Cure FSHD.

Avidity Biosciences (Nasdaq: RNA), a biopharmaceutical company developing Antibody Oligonucleotide Conjugates (AOCs™), has announced its participation in two upcoming investor conferences. The company will present at the Wells Fargo 2024 Healthcare Conference on September 4 at 5:00 a.m. PT / 8:00 a.m. ET and the Cantor Global Healthcare Conference on September 17 at 6:45 a.m. PT / 9:45 a.m. ET.

Investors and interested parties can access live webcasts and archived replays of both events through the 'Events and Presentations' page in the 'Investors' section of Avidity's website. This participation in major healthcare conferences demonstrates Avidity's commitment to engaging with investors and showcasing its progress in developing innovative RNA therapeutics.